Literature DB >> 1737371

Cytokine responses to intraventricular injection of interleukin 2 into patients with leptomeningeal carcinomatosis: rapid induction of tumor necrosis factor alpha, interleukin 1 beta, interleukin 6, gamma-interferon, and soluble interleukin 2 receptor (Mr 55,000 protein).

J List1, R P Moser, M Steuer, W G Loudon, J B Blacklock, E A Grimm.   

Abstract

Interleukin 2 (IL-2) is a potent immunostimulant that causes the release of secondary cytokines and the production of lymphokine-activated killer cells. We investigated the cellular and cytokine responses to injection of recombinant human IL-2 into the human cerebrospinal fluid of 11 patients with metastatic tumors involving the spinal or cerebral leptomeninges. After initial intraventricular IL-2 administration (1.25 x 10(5) to 2 x 10(6) Cetus units/injection), cerebrospinal fluid samples were collected at intervals from 0 to 24 h. Enzyme-linked immunosorbent assay results indicated that IL-2 levels gradually decreased during the first 24 h, with an average t1/2 between 4 and 8 h. Induction of tumor necrosis factor alpha, interleukin 1 beta, interleukin 6, gamma-interferon, and interleukin 2 receptor (p55) was also assessed by enzyme-linked immunosorbent assay. Tumor necrosis factor alpha and interleukin 6 levels peaked at 2 to 4 h and 4 to 6 h, with concentrations between 71 to 1,714 pg/ml and 942 to 10,500 pg/ml, respectively. Interleukin 1 beta, gamma-interferon, and soluble IL-2 receptor peaked later, during 6 to 12 h; the levels achieved were 234 pg/ml, 25 NIH units/ml, and 207 units/ml, respectively. All cytokine concentrations returned to near baseline between 12 and 24 h; however, the soluble IL-2 receptor levels remained elevated. Additional observations included a rapid influx of neutrophilic leukocytes, followed by a prolonged presence of lymphocytes. These data indicate a broad and complex potential of the immune response in the central nervous system, as well as further define the cytokine cascade in response to IL-2 alone.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1737371

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

Review 1.  Interleukins. Clinical pharmacology and therapeutic use.

Authors:  W E Aulitzky; M Schuler; C Peschel; C Huber
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

2.  Intrathecal immunotherapy in CNS tumors disseminating via CSF: preliminary evaluation using different treatment schedules.

Authors:  A Salmaggi; A Dufour; A Silvani; E Ciusani; A Nespolo; A Boiardi
Journal:  Ital J Neurol Sci       Date:  1996-08

3.  Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model.

Authors:  Ling-Yuan Kong; Alexander Gelbard; Jun Wei; Chantal Reina-Ortiz; Yongtao Wang; Eric C Yang; Yared Hailemichael; Izabela Fokt; Arumugam Jayakumar; Wei Qiao; Gregory N Fuller; Willem W Overwijk; Waldemar Priebe; Amy B Heimberger
Journal:  Clin Cancer Res       Date:  2010-04-13       Impact factor: 12.531

Review 4.  Leptomeningeal metastases from solid malignancy: a review.

Authors:  Sophie Taillibert; Florence Laigle-Donadey; Catherine Chodkiewicz; Marc Sanson; Khê Hoang-Xuan; Jean-Yves Delattre
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

5.  Brain Tumor Working Group Report on the 9th International Conference on Brain Tumor Research and Therapy. Organ System Program, National Cancer Institute.

Authors:  D F Deen; A Chiarodo; E A Grimm; J R Fike; M A Israel; L E Kun; V A Levin; L J Marton; R J Packer; A E Pegg
Journal:  J Neurooncol       Date:  1993-06       Impact factor: 4.130

6.  Intrathecal treatment of C6 glioma leptomeningeal metastasis in Wistar rats with interleukin-2.

Authors:  U Herrlinger; R Buchholz; P Jachimczak; M Schabet
Journal:  J Neurooncol       Date:  1996-03       Impact factor: 4.130

Review 7.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

8.  Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report.

Authors:  Isabella C Glitza; Cara Haymaker; Chantale Bernatchez; Luis Vence; Michelle Rohlfs; Jessie Richard; Carol Lacey; Rahmatu Mansaray; Orenthial J Fulbright; Renjith Ramachandran; Christopher Toth; Seth Wardell; Sapna P Patel; Scott E Woodman; Wen-Jen Hwu; Laszlo G Radvanyi; Michael A Davies; Nicholas E Papadopoulos; Patrick Hwu
Journal:  Cancer Immunol Res       Date:  2015-07-27       Impact factor: 11.151

Review 9.  New aspects of immunotherapy of leptomeningeal metastasis.

Authors:  U Herrlinger; M Weller; M Schabet
Journal:  J Neurooncol       Date:  1998 Jun-Jul       Impact factor: 4.130

Review 10.  Effects of route and formulation on clinical pharmacokinetics of interleukin-2.

Authors:  P M Anderson; M A Sorenson
Journal:  Clin Pharmacokinet       Date:  1994-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.